Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment
Monica Grover1, Laura K Bachrach2
1Department of Pediatrics, Division of Endocrinology, School of Medicine, Stanford University, Room H314, Stanford, CA, 94305, USA.
Insights
Pediatric osteoporosis, a complication of chronic illness, requires early intervention. This review covers risk factors, diagnosis, and treatment for childhood bone fragility.
Area of Science:
- Pediatric endocrinology
- Bone health in children
- Chronic illness complications
Background:
- Osteoporosis is an under-recognized complication in children with chronic illnesses.
- Early bone fragility presents significant challenges in pediatric care.
Purpose of the Study:
- To review recent literature on risk factors, evaluation, and treatment of pediatric osteoporosis.
- To highlight the importance of early bone fragility management in children.
Main Methods:
- Literature review of recent studies on pediatric osteoporosis.
- Synthesis of information on risk factors, diagnostic criteria, and therapeutic approaches.
Main Results:
- Pediatric osteoporosis diagnosis involves low trauma vertebral fractures or low bone mineral density with long bone fractures.
- Vertebral fracture screening is crucial, as fractures are common and often asymptomatic.
- Pharmacologic treatment, particularly bisphosphonates, is recommended for fragility fractures, though optimal protocols are debated.
- Newer osteoporosis drugs require further pediatric testing.
Conclusions:
- Increased attention to risk factors, early intervention, and further research are essential to reduce fragility fractures in children.
- Optimizing therapy and prevention strategies for pediatric osteoporosis are critical areas for future investigation.
Purpose Of Review:
Osteoporosis is an under-recognized complication of chronic illness in childhood. This review will summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility.
Recent Findings:
Criteria for the diagnosis of pediatric osteoporosis include the presence of low trauma vertebral fractures alone or the combination of low bone mineral density and several long bone fractures. Monitoring for bone health may include screening for vertebral fractures that are common but often asymptomatic. Pharmacologic agents should be offered to those with fragility fractures especially when spontaneous recovery is unlikely. Controversies persist about the optimal bisphosphonate agent, dose, and duration. Newer osteoporosis drugs have not yet been adequately tested in pediatrics, though clinical trials are underway. The prevalence of osteoporosis is increased in children with chronic illness. To reduce the frequency of fragility fractures requires increased attention to risk factors, early intervention, and additional research to optimize therapy and potentially prevent their occurrence.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Chronic Kidney Disease IV: Nursing Management
Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care

